Grifols SA (NASDAQ:GRFS)

15.72
Delayed Data
As of 3:59pm ET
 -0.16 / -1.01%
Today’s Change
13.40
Today|||52-Week Range
25.73
-32.50%
Year-to-Date
CSL Limited: A Twindemic Can Unravel A Pricey Premium
Sep 13 / Seeking Alpha - Paid Partner Content
Does convalescent plasma help COVID-19 patients? Studies will answer
Aug 29 / Seeking Alpha - Paid Partner Content
Grifols to acquire remaining stake in Alkahest for $146M
Sep 08 / Seeking Alpha - Paid Partner Content
RIG, RKT among premarket gainers
Aug 24 / Seeking Alpha - Paid Partner Content
NIH begs to differ on FDA's EUA for convalescent plasma for COVID-19
Sep 01 / Seeking Alpha - Paid Partner Content
Convalescent plasma players rally on FDA emergency use nod
Aug 24 / Seeking Alpha - Paid Partner Content
FDA to fast-track COVID-19 vaccine - Financial Times
Aug 31 / Seeking Alpha - Paid Partner Content
FDA allows emergency use of convalescent plasma to treat COVID-19
Aug 23 / Seeking Alpha - Paid Partner Content

Today’s Trading

Previous close15.88
Today’s open15.99
Day’s range15.69 - 15.99
Volume29,304
Average volume (3 months)1,258,767
Market cap$4.2B
Data as of 3:59pm ET, 09/22/2020

Growth & Valuation

Earnings growth (last year)-0.65%
Earnings growth (this year)+3.26%
Earnings growth (next 5 years)+12.29%
Revenue growth (last year)+7.81%
P/E ratio16.6
Price/Sales2.80
Price/Book2.04

Competitors

 Today’s
change
Today’s
% change
ARNAArena Pharmaceutical...+3.19+4.52%
CBPOChina Biologic Produ...-0.37-0.33%
ALLKAllakos Inc-0.52-0.65%
----
Data as of 6:23pm ET, 09/22/2020

Financials

Next reporting dateNovember 10, 2020
EPS forecast (this quarter)$0.31
Annual revenue (last year)$5.7B
Annual profit (last year)$699.7M
Net profit margin12.26%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
No executives to display
Corporate headquarters
Barcelona, Catalonia

Forecasts